Alger Health Sciences C
Alger Funds111 Fifth AvenueNew York, NY 10003
Map
Phone: 800-992-3863
| Category: | Health | | Fund Family: | Alger | | Net Assets: | 183.57M | | Year-to-Date Return: | 6.34% | | Yield: | 0.00% | | Morningstar Rating: |  | | Fund Inception Date: | Apr 30, 2002 |
|
Dan C. Chung
Lead Manager since Oct 6, 2005 | | | Dan C. Chung, CFA is Chief Executive Officer and Chief Investment Officer. He is Portfolio Manager of the Alger Mid Cap Growth, Alger Health Sciences, Alger Large Cap Growth, Alger SMid Cap Growth, Alger China-U.S. Growth, Alger Analyst, Alger Dynamic Opportunities, and Alger Growth & Income portfolios. Dan joined Alger in 1994 and has 17 years of investment experience. He was named Chief Investment Officer in September 2001, President in 2003, and CEO in 2006. Dan graduated from Stanford University and earned his J.D. from Harvard Law School in 1987. After completing law school, he served a one-Year term as Judicial Clerk for the Honorable Justice Anthony M. Kennedy, United States Supreme Court. He joined Simpson Thacher & Bartlett LLP in New York City in 1989 and earned an L.L.M. from New York University. Dan is a CFA charterholder and a member of the CFA Institute. |
| Min Initial Investment: | 1,000 | | Min Initial Investment, IRA: | 500 | | Min Initial Investment, AIP: | 500 | | Min Subsequent Investment: | 50 | | Min Subsequent Investment, IRA: | 50 | | Min Subsequent Investment, AIP: | 50 |
|
| |
| The investment seeks long-term capital appreciation.
The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies of any market capitalization that are engaged in the health sciences sector. It can also invest in derivative instruments. |
| Last Dividend
:
| 0.00 | | Last Cap Gain
(Dec 17, 2012)
:
| 0.00 | | Annual Holdings Turnover
(Jun 16, 2013)
:
| 110.37% | | Average for Category: | 47.95% |
|
| Expense | AHSCX | Category Avg |
|---|
| Annual Report Expense Ratio (net): | 2.14% | 1.48% | | Prospectus Net Expense Ratio: | 2.14% | N/A | | Prospectus Gross Expense Ratio: | 2.14% | N/A | | Max 12b1 Fee: | 1.00% | N/A | | Max Front End Sales Load: | N/A | 5.28% | | Max Deferred Sales Load:
| 1.00% | 2.66% | | 3 Yr Expense Projection*: | 670 | 646 | | 5 Yr Expense Projection*: | 1,149 | 1,001 | | 10 Yr Expense Projection*: | 2,472 | 1,973 |
|
|
0.14(0.67%) Jun 18